How the liver affects a new medicine
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new medicine for people with mild or moderate liver problems to see how the liver affects the drug in the body. It also includes people with normal liver function for comparison.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 or older
- Weigh at least 45 kg (if female) or 50 kg (if male)
- Have either stable mild or moderate liver disease (Child-Pugh Class A or B) or be a healthy volunteer matched to those participants
- Not regularly drink more than 14 alcoholic drinks per week
- Be willing to stop all other medications and supplements for 14 days before the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This study checks how a new medicine (called NNC0487-0111) moves through the body and how safe it is for people with different levels of liver function. If you have stable liver disease or normal liver function, you might help researchers learn how the medicine works.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
This study looks at how the body handles a new investigational drug (HS-10504) in people with liver problems compared to those with healthy liver function.
This study looks at how a new oral drug (HS-10241) is processed by the body in people with mild to moderate liver disease and in healthy people. It helps find the right dose and safety for future patients with liver problems.
This study looks at how a new oral drug (called INCB161734) is processed by the body and how safe it is in people with liver problems. It may help doctors understand the right dose for patients with liver impairment.
Hear when a new Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.